Mostrar el registro sencillo del documento

dc.creatorNicol, Thomas
dc.creatorLefeuvre, Caroline
dc.creatorSerri, Orianne
dc.creatorPivert, Adeline
dc.creatorJoubaud, Françoise
dc.creatorDubée, Vincent
dc.creatorKouatchet, Achille
dc.creatorDucancelle, Alexandra
dc.creatorLunel-Fabiani, Françoise
dc.creatorLe Guillou-Guillemette, Hélène
dc.date.accessioned2020-07-27T22:11:50Z
dc.date.available2020-07-27T22:11:50Z
dc.date.created2020-08
dc.identifier.issn1386-6532spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S1386653220302535?via%3Dihubspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/11248
dc.format.extent7 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherJournal of Clinical Virologyeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectInmunoensayos automatizadosspa
dc.titleAssessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.subject.keywordPerformancespa
dc.subject.keywordAutomated immunoassaysspa
dc.subject.keywordLateral flow immunoassayspa
dc.identifier.doihttps://doi.org/10.1016/j.jcv.2020.104511spa
dc.description.abstractenglishBackground The emergence of new SARS-CoV-2 has promoted the development of new serological tests that could be complementary to RT-PCR. Nevertheless, the assessment of clinical performances of available tests is urgently required as their use has just been initiated for diagnose. Objectives The aim of this study was to assess the performance of three immunoassays for the detection of SARS-CoV-2 antibodies. Methods Two automated immunoassays (Abbott SARS-CoV-2 CLIA IgG and Euroimmun Anti-SARS-CoV-2 ELISA IgG/IgA assays) and one lateral flow immunoassay (LFIA NG-Test® IgG-IgM COVID-19) were tested. 293 specimens were analyzed from patients with a positive RT-PCR response, from patients with symptoms consistent with COVID-19 but exhibiting a negative response to the RT-PCR detection test, and from control group specimens. Days since symptoms onset were collected from clinical information sheet associated with respiratory tract samples. Results Overall sensitivity for IgG was equivalent (around 80 %) for CLIA, ELISA and LFIA. Sensitivity for IgG detection, >14 days after onset of symptoms, was 100.0 % for all assays. Overall specificity for IgG was greater for CLIA and LFIA (more than 98 %) compared to ELISA (95.8 %). Specificity was significantly different between IgA ELISA (78.9 %) and IgM LFIA (95.8 %) (p < 0.05). The best agreement was observed between CLIA and LFIA assays (97 %; k = 0.936). Conclusion Excellent sensitivity for IgG detection was obtained >14 days after onset of symptoms for all immunoassays. Specificity was also excellent for IgG CLIA and IgG LFIA. Our study shows that NG-Test® is reliable and accurate for routine use in clinical laboratories.spa


Archivos en el documento

Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento